中文名稱:地塞米松磷酸鈉 | 英文名稱:Dexamethasone Sodium Phosphate |
CAS:55203-24-2 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.83% | 產(chǎn)品類別: 抑制劑 |
貨號: T6465 |
名稱 | Dexamethasone Sodium Phosphate |
描述 | Dexamethasone Sodium Phosphate (Dexadreson) , an interleukin receptor modulator, has anti-inflammatory and immunosuppressant effects. It belongs to a potent glucocorticoid class of steroid synthetic drugs. |
激酶實(shí)驗(yàn) | Biochemical kinase assays: Recombinant His-tagged human Aurora-A protein is expressed in Escherichia coli and is purified with HisTrap HP column. Purified recombinant human Aurora-B and Aurora-C protein are purchased. Experiments are done in quintuplicate in 96-well plates. The Aurora-A assay reaction is conducted in the presence of 20 μM ATP, 25 μM Tetra-Kemptide [RRR(GLRRASLG)4R-NH2], 1.0 μCi per well [γ-33P]-ATP, 0.1 ng per well Aurora-A in 50 mM Tris-HCl (pH 7.4), 15 mM Mg(OAc)2, and 0.2 mM EDTA at 30°C for 40 minutes. To investigate the inhibition mode of MK-5108 for Aurora-A, the IC50 values of MK-5108 are determined in the presence of different concentrations of ATP. Then, the IC50 value is plotted as a function of ATP concentration to analyze the effect of ATP concentration on the IC50 value of MK-5108. The Aurora-B assay reaction is conducted in the presence of 15 μM ATP, 100 μM Kemptide (GLRRASLG-NH2), 1.0 μCi per well [γ-33P]-ATP, 5.0 ng per well Aurora-B in 50 mM Tris-HCl (pH 7.4), 15 mM Mg(OAc)2, and 0.2 mM EDTA at 30 °C for 20 minuts. The Aurora-C assay reaction is conducted in the presence of 40 μM ATP, 100 μM Kemptide, 1.0 μCi per well [γ-33P]-ATP, 15 ng per well Aurora-C in 10 mM MOPS-NaOH (pH 7.4), 5 mM Mg(OAc)2, 1 mM (±) DTT, and 1 mM EGTA at 30 °C for 20 minutes. After kinase reactions are terminated by adding 2.0% phosphoric acid, Tetra-Kemptide or Kemptide is trapped on the MultiScreen-PH plate. Wells are washed five times with 0.64% phosphoric acid and then monitored for radioactivity in a liquid scintillation counter. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : Slightly soluble |
關(guān)鍵字 | 2392-39-4 | Dexamethasone Sodium Phosphate |
相關(guān)產(chǎn)品 | Revaprazan hydrochloride | Diallyl disulfide | Ibuprofen | Paradol | Dexamethasone | Glafenine | Acetaminophen | Diclofenac Potassium | Salicylamide | Salicylic acid | Bismuth Subsalicylate | Diclofenac sodium |
相關(guān)庫 | 抗癌活性化合物庫 | 抗癌上市藥物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | EMA 上市藥物庫 | 抗衰老化合物庫 | FDA 上市藥物庫 | 疼痛相關(guān)化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (13年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP6年
|
湖北阡陌生物科技有限公司
|
2025-04-17 | |
¥345 |
VIP10年
|
滄州恩科醫(yī)藥科技有限公司
|
2025-04-17 | |
詢價 |
VIP1年
|
銘龍(咸寧)醫(yī)藥有限公司
|
2025-04-17 | |
詢價 |
VIP4年
|
湖北興琰新材料科技有限公司
|
2025-04-17 | |
¥7500 |
VIP2年
|
江蘇榮碩藥業(yè)有限公司
|
2025-04-17 | |
¥5800 |
VIP1年
|
江蘇輝潤藥業(yè)有限公司
|
2025-04-17 | |
詢價 |
VIP1年
|
滄州恩科醫(yī)藥科技有限公司
|
2025-04-16 | |
詢價 |
湖北瑞森蒂克生物科技有限公司
|
2025-04-15 | ||
¥155.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 | |
詢價 |
VIP4年
|
陜西締都醫(yī)藥化工有限公司
|
2025-03-14 |